Drug intelligence / Profile preview

RGV-DO-003

Development stage: Preclinical
Lead developer: RNAGene
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RGV-DO-003 is a prophylactic vaccine candidate developed by RNAGENE for the prevention of COVID-19. It is being investigated primarily for infectious and respiratory diseases, with its main active indication being COVID-19. As of March 2025, the drug remains in preclinical development and has not yet entered clinical trials or received regulatory approval. The specific mechanism of action, molecular target(s), and detailed modality have not been publicly disclosed[1][5].

Beyond the preview

Go deeper on RGV-DO-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGV-DO-003.

Explore the full profile